GO:0047391 alkylglycerophosphoethanolamine phosphodiesterase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0047391 describes the molecular function of alkylglycerophosphoethanolamine phosphodiesterase, which hydrolyzes 1-alkyl-sn-glycero-3-phosphoethanolamine to ethanolamine and 1-alkyl-sn-glycerol 3-phosphate.
• This activity is synonymous with lysophospholipase D activity and is best known as the enzymatic function of autotaxin (ENPP2), a secreted enzyme that generates lysophosphatidic acid (LPA).
• Autotaxin/ENPP2 is the principal enzyme responsible for lysophospholipase D activity in biological fluids, and its product LPA signals through six G-protein-coupled receptors to regulate cell proliferation, migration, and survival.
• Dysregulated autotaxin-LPA signaling is implicated in cancer progression, including pancreatic cancer and chronic lymphocytic leukemia, as well as in pulmonary fibrosis and neuroinflammation.
• Studying GO:0047391 requires integrating enzyme assays, lipidomics, receptor signaling readouts, and CRISPR-based genetic models to dissect its role in health and disease.
• EDITGENE provides CRISPR knockout, point-mutation, knock-in, overexpression cell models and library screening services to accelerate functional studies of alkylglycerophosphoethanolamine phosphodiesterase activity and its downstream pathways.
Description
Alkylglycerophosphoethanolamine phosphodiesterase activity (GO:0047391) is a molecular function defined by the hydrolysis of 1-alkyl-sn-glycero-3-phosphoethanolamine to ethanolamine and 1-alkyl-sn-glycerol 3-phosphate. This activity is also known as lysophospholipase D activity and is a critical component of lysophospholipid metabolism, a network of enzymatic reactions that generates bioactive lipid mediators. The enzyme most extensively characterized for this activity is autotaxin (ENPP2), a secreted glycoprotein that hydrolyzes lysophosphatidylcholine to produce lysophosphatidic acid (LPA), a potent signaling molecule. Although the canonical reaction of autotaxin uses lysophosphatidylcholine as substrate, its lysophospholipase D activity extends to other lysophospholipids, including alkylglycerophosphoethanolamine, underscoring the broad substrate specificity of this enzyme. Researchers study GO:0047391 because its product, LPA, regulates diverse cellular processes such as proliferation, migration, survival, and cytokine production through activation of at least six G-protein-coupled receptors (LPAR1-6). Dysregulated LPA signaling is a hallmark of numerous pathological conditions, including cancer, fibrosis, and neuroinflammatory diseases. Understanding the enzymatic activity and regulation of alkylglycerophosphoethanolamine phosphodiesterase is therefore essential for developing therapeutic strategies that target this pathway. This article provides a comprehensive overview of GO:0047391, covering its definition, biological significance, key genes, regulatory mechanisms, disease associations, and state-of-the-art research methods, including CRISPR-based approaches for functional interrogation.
alkylglycerophosphoethanolamine phosphodiesterase activity At A Glance
| GO ID | GO:0047391 |
|---|---|
| GO term | alkylglycerophosphoethanolamine phosphodiesterase activity |
| Ontology | molecular_function |
| Synonym | 1-alkyl-sn-glycero-3-phosphoethanolamine ethanolaminehydrolase activity; lysophospholipase D activity |
| Definition | Catalysis of the reaction: H2O + 1-alkyl-sn-glycero-3-phosphoethanolamine = ethanolamine + 1-alkyl-sn-glycerol 3-phosphate. |
| Major function | Hydrolysis of alkylglycerophosphoethanolamine to produce ethanolamine and 1-alkyl-sn-glycerol 3-phosphate; also acts on lysophosphatidylcholine to generate lysophosphatidic acid (LPA). |
| Representative enzyme | Autotaxin (ENPP2), a secreted lysophospholipase D. |
| Pathway context | Lysophospholipid metabolism; LPA signaling. |
| Disease relevance | Cancer, fibrosis, neuroinflammation, and other LPA-driven pathologies. |
What Is GO:0047391?
GO:0047391, alkylglycerophosphoethanolamine phosphodiesterase activity, is defined as the catalysis of the reaction: H2O + 1-alkyl-sn-glycero-3-phosphoethanolamine = ethanolamine + 1-alkyl-sn-glycerol 3-phosphate. In other words, this enzymatic activity cleaves a specific lysophospholipid, releasing ethanolamine and generating a lysophosphatidic acid-like molecule. The term is synonymous with 1-alkyl-sn-glycero-3-phosphoethanolamine ethanolaminehydrolase activity and lysophospholipase D activity. It belongs to the molecular_function ontology aspect and is involved in lipid catabolic processes and phospholipid metabolism.
Why Is alkylglycerophosphoethanolamine phosphodiesterase activity Important in Cell Biology?
GO:0047391 is important because it represents the enzymatic activity that produces lysophosphatidic acid (LPA), a bioactive lipid with profound effects on cell behavior and tissue homeostasis. The principal enzyme exhibiting this activity, autotaxin (ENPP2), is overexpressed in various cancers and contributes to tumor progression, metastasis, and resistance to therapy. In fibrotic diseases such as pulmonary fibrosis, LPA signaling promotes fibroblast recruitment and activation, making this pathway a promising therapeutic target. In the nervous system, LPA produced by autotaxin modulates microglial activation and neuroinflammation, with implications for neurodegenerative conditions. Thus, understanding the regulation and function of alkylglycerophosphoethanolamine phosphodiesterase activity is critical for both basic biology and translational medicine.
• Generates lysophosphatidic acid (LPA), a key signaling lipid that regulates proliferation, migration, and survival.
• Autotaxin (ENPP2), the main enzyme with this activity, is a secreted protein that acts in the tumor microenvironment to promote cancer progression.
• LPA signaling through LPAR1 is implicated in pulmonary fibrosis, and inhibition of this receptor is being explored as a treatment.
• In microglia, LPA-induced MAPK signaling drives inflammatory responses, linking this activity to neuroinflammation.
• ENPP2 expression is elevated in chronic lymphocytic leukemia and promotes lipid accumulation via AMPK/SREBP1/FAS pathway.
• Small-molecule inhibitors of autotaxin, such as benzoxaboroles, have been developed, highlighting the druggability of this activity.
• The enzyme's lysophospholipase D activity is a central node in lysophosphatidylcholine metabolism, affecting diverse human diseases.
• Understanding the structure-function relationship of autotaxin provides insights into substrate specificity and catalytic mechanism.
• CRISPR-based models allow precise dissection of the role of this activity in physiological and pathological contexts.
• Targeting this activity could have therapeutic benefits in cancer, fibrosis, and inflammatory diseases.
What Happens During alkylglycerophosphoethanolamine phosphodiesterase activity?
Substrate recognition and binding
In simple terms: The enzyme grabs a specific lipid molecule from the membrane or extracellular space.
Alkylglycerophosphoethanolamine phosphodiesterase, exemplified by autotaxin (ENPP2), recognizes and binds its substrate, 1-alkyl-sn-glycero-3-phosphoethanolamine, within a hydrophobic pocket. The enzyme also accepts lysophosphatidylcholine as a substrate, reflecting its broad specificity as a lysophospholipase D. Structural studies have revealed that autotaxin possesses a bimetallic active site with two zinc ions that coordinate the phosphate group of the substrate, facilitating nucleophilic attack.
Catalytic hydrolysis
In simple terms: The enzyme uses water to split the lipid, releasing two products.
The catalytic mechanism involves a water molecule activated by the zinc ions, which attacks the phosphorus atom of the substrate, leading to cleavage of the phosphodiester bond. This hydrolysis releases ethanolamine and 1-alkyl-sn-glycerol 3-phosphate. For the canonical substrate lysophosphatidylcholine, the products are choline and lysophosphatidic acid (LPA). The reaction is dependent on the presence of divalent cations, particularly zinc, for activity.
Product release and signaling
In simple terms: The products are released and can trigger cellular responses.
Following catalysis, the products diffuse away from the active site. LPA, the major bioactive product, acts as an extracellular ligand for G-protein-coupled receptors (LPAR1-6), initiating intracellular signaling cascades that regulate cell proliferation, migration, and survival. In microglia, LPA activates MAPK signaling to induce inflammatory responses. In cancer cells, LPA promotes progression and lipid accumulation via the AMPK/SREBP1/FAS pathway.
Regulation of enzyme activity
In simple terms: The enzyme's activity is controlled at multiple levels to fine-tune LPA production.
Autotaxin activity is regulated by its expression level, secretion, and interaction with the extracellular matrix. Its enzymatic activity can be modulated by lipid environment and post-translational modifications. Additionally, the LPA produced is rapidly degraded by lipid phosphate phosphatases, ensuring tight spatial and temporal control of signaling. Inhibitors such as benzoxaboroles can block autotaxin activity, providing tools to study its function.
Key Genes Involved in GO:0047391 alkylglycerophosphoethanolamine phosphodiesterase activity
The following genes are directly or indirectly involved in alkylglycerophosphoethanolamine phosphodiesterase activity, its regulation, or downstream signaling.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ENPP2 | Encodes autotaxin, the principal enzyme with lysophospholipase D activity | Central to LPA production; target in cancer and fibrosis |
| LPAR1 | LPA receptor 1, mediates many LPA-induced cellular responses | Therapeutic target in pulmonary fibrosis |
| LPAR2 | LPA receptor 2, involved in cell migration and survival | Implicated in cancer and inflammation |
| LPAR3 | LPA receptor 3, regulates cell proliferation and differentiation | Studied in neuroinflammation and cancer |
| LPAR4 | LPA receptor 4, contributes to vascular development | Potential role in development and disease |
| LPAR5 | LPA receptor 5, modulates immune cell function | Linked to inflammatory responses |
| LPAR6 | LPA receptor 6, involved in hair follicle development | Rare mutations cause hair disorders |
| PLA2G7 | Lipoprotein-associated phospholipase A2, produces lysophosphatidylcholine | Provides substrate for autotaxin |
| LCAT | Lecithin-cholesterol acyltransferase, influences lysophosphatidylcholine levels | Modulates substrate availability |
| LPP1 | Lipid phosphate phosphatase 1, degrades LPA | Terminates LPA signaling |
| LPP3 | Lipid phosphate phosphatase 3, degrades LPA | Regulates LPA gradients |
| GNA12 | G-protein alpha 12, mediates LPA signaling | Downstream effector |
| GNA13 | G-protein alpha 13, mediates LPA signaling | Downstream effector |
| RHOA | RhoA GTPase, regulates cytoskeleton | Downstream of LPA receptors |
| MAPK1 | ERK2, MAP kinase | Mediates LPA-induced proliferation |
| MAPK3 | ERK1, MAP kinase | Mediates LPA-induced proliferation |
| AKT1 | AKT serine/threonine kinase 1 | Survival signaling downstream of LPA |
How Is alkylglycerophosphoethanolamine phosphodiesterase activity Regulated?
The activity of alkylglycerophosphoethanolamine phosphodiesterase is primarily regulated by the expression and secretion of autotaxin (ENPP2). ENPP2 transcription can be induced by growth factors and inflammatory cytokines. At the protein level, autotaxin activity is influenced by its interaction with integrins and heparan sulfate proteoglycans, which localize the enzyme to the cell surface or extracellular matrix. The product LPA is rapidly degraded by lipid phosphate phosphatases (LPP1-3), which terminate signaling. Additionally, LPA signaling is modulated by receptor expression levels and the availability of downstream G-proteins. In pathological conditions, such as cancer, ENPP2 is often overexpressed, leading to elevated LPA levels that promote tumor progression.
alkylglycerophosphoethanolamine phosphodiesterase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ENPP2 | Pancreatic cancer progression | Knockout of ENPP2 in cancer-associated fibroblasts; xenograft models |
| ENPP2 | Chronic lymphocytic leukemia | Overexpression or knockout in CLL cell lines; lipid accumulation assays |
| LPAR1 | Pulmonary fibrosis | LPAR1 knockout mice; bleomycin-induced fibrosis model |
| LPAR2 | Neuroinflammation | Microglia-specific knockout; LPS-induced inflammation models |
| ENPP2 | Cancer (general) | CRISPR knockout in tumor cells; in vivo tumor growth assays |
Cancer
Autotaxin (ENPP2) and its product LPA are strongly implicated in cancer. In pancreatic cancer, a stromal lysolipid-autotaxin signaling axis promotes tumor progression, with cancer-associated fibroblasts secreting autotaxin that acts on tumor cells. In chronic lymphocytic leukemia, ENPP2 promotes progression and lipid accumulation via the AMPK/SREBP1/FAS pathway. Elevated autotaxin levels correlate with poor prognosis in various cancers, making it an attractive therapeutic target.
Pulmonary fibrosis
LPA signaling through LPAR1 contributes to the pathogenesis of pulmonary fibrosis by promoting fibroblast recruitment, proliferation, and collagen deposition. Inhibition of LPAR1 has been proposed as a potential treatment for pulmonary fibrosis. Autotaxin, by generating LPA, is a key upstream regulator of this fibrotic process, and its inhibition is being explored as a therapeutic strategy.
Neuroinflammation and neurodegeneration
In the central nervous system, LPA produced by autotaxin activates microglia and induces inflammatory responses via MAPK signaling. This neuroinflammatory response is implicated in neurodegenerative diseases such as multiple sclerosis and Alzheimer's disease. Modulating autotaxin activity or LPA receptor signaling could therefore have therapeutic potential in neuroinflammatory conditions.
Other LPA-related pathologies
Dysregulated LPA signaling has been linked to a wide range of diseases, including atherosclerosis, osteoporosis, and reproductive disorders. The multimodal and multinodal signaling networks of LPA underscore the importance of tightly regulating its production by enzymes like autotaxin. Understanding the role of alkylglycerophosphoethanolamine phosphodiesterase activity in these contexts may reveal new therapeutic opportunities.
From alkylglycerophosphoethanolamine phosphodiesterase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ENPP2 reduce LPA levels and tumor growth? | ENPP2 knockout cancer cell lines and xenografts |
| What is the effect of a specific point mutation in the catalytic site of ENPP2? | Point-mutation knock-in of catalytically dead ENPP2 |
| Can overexpression of ENPP2 drive fibrosis? | Transgenic overexpression of ENPP2 in mouse lung |
| How does LPAR1 signaling contribute to neuroinflammation? | LPAR1 knockout microglia and neuroinflammation models |
| What is the role of ENPP2 in lipid metabolism? | Knockout hepatocytes and lipidomics |
| Can CRISPR activation of ENPP2 increase LPA production? | CRISPRa overexpression in cell lines |
How to Study the alkylglycerophosphoethanolamine phosphodiesterase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lysophospholipase D activity assay | Enzymatic hydrolysis of substrate | Characterizing autotaxin activity and inhibitors |
| LC-MS lipidomics | LPA and lysophospholipid levels | Quantifying LPA in cells and tissues |
| Western blot for phospho-ERK | MAPK pathway activation | Assessing LPA-induced signaling |
| RhoA activation assay | GTP-bound RhoA levels | Measuring downstream LPA effects |
| CRISPR knockout screen | Gene essentiality or modifier effects | Identifying regulators of LPA production |
| qRT-PCR | ENPP2 mRNA expression | Validating transcriptional changes |
| Immunohistochemistry | Autotaxin protein localization | Tissue distribution studies |
| Inhibitor profiling | IC50 of small molecules | Drug discovery for autotaxin inhibitors |
Enzymatic activity assays
Lysophospholipase D activity can be measured using fluorogenic or radiolabeled substrates, such as lysophosphatidylcholine analogs. These assays quantify the release of choline or ethanolamine, providing direct readout of enzyme activity. They are essential for characterizing autotaxin inhibitors and for studying enzyme kinetics.
Lipidomics and mass spectrometry
Mass spectrometry-based lipidomics allows comprehensive profiling of lysophospholipids, including LPA and its precursors. This approach can quantify changes in LPA levels in response to genetic or pharmacological manipulation of alkylglycerophosphoethanolamine phosphodiesterase activity. It is particularly useful for identifying substrate specificity and product formation in biological samples.
Cell signaling assays
Downstream LPA signaling can be monitored by measuring phosphorylation of MAPK/ERK, AKT, and RhoA activation. These assays use Western blotting, phospho-specific antibodies, or reporter systems to assess pathway activation in response to LPA or autotaxin modulation. They help link enzyme activity to cellular responses.
CRISPR-based genetic screens
Genome-wide CRISPR knockout or activation screens can identify genes that regulate LPA production or signaling. For example, screens for modifiers of autotaxin expression or LPA-induced phenotypes can uncover novel components of the pathway. These functional genomics approaches are powerful for discovering therapeutic targets.
How CRISPR Can Be Used to Study GO:0047391 alkylglycerophosphoethanolamine phosphodiesterase activity
Knockout
CRISPR knockout of ENPP2 or LPA receptors (LPAR1-6) in cell lines and animal models enables loss-of-function studies to determine their role in LPA production and signaling. For example, ENPP2 knockout in cancer cells reduces LPA levels and impairs tumor growth. Knockout of LPAR1 in mice attenuates pulmonary fibrosis.
Point Mutation
Introducing point mutations in the catalytic domain of ENPP2 (e.g., mutations in zinc-coordinating residues) can generate catalytically dead enzymes, allowing separation of enzymatic activity from other functions. Such models are valuable for dissecting the contribution of lysophospholipase D activity to specific phenotypes.
Knock-in
Knock-in of tagged ENPP2 (e.g., FLAG or GFP) allows visualization and purification of the enzyme for biochemical and imaging studies. Knock-in of disease-associated mutations can model human conditions. For example, knock-in of a mutation that increases ENPP2 activity could mimic pathological LPA overproduction.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of ENPP2 can elevate LPA levels and drive phenotypes such as cell proliferation, migration, and fibrosis. Overexpression models are useful for gain-of-function studies and for testing therapeutic inhibitors.
How EDITGENE Supports alkylglycerophosphoethanolamine phosphodiesterase activity Research
Researchers studying alkylglycerophosphoethanolamine phosphodiesterase activity-related genes often need to determine whether a candidate gene is causally involved in LPA production, signaling, or disease phenotypes. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this functional validation, from gene knockout to precise point mutations and overexpression models.
Contact EDITGENE today to design your custom CRISPR model for alkylglycerophosphoethanolamine phosphodiesterase activity research.
Frequently Asked Questions About alkylglycerophosphoethanolamine phosphodiesterase activity
What is alkylglycerophosphoethanolamine phosphodiesterase activity?
It is a molecular function defined by GO:0047391, catalyzing the hydrolysis of 1-alkyl-sn-glycero-3-phosphoethanolamine to ethanolamine and 1-alkyl-sn-glycerol 3-phosphate. It is also known as lysophospholipase D activity.
What genes are involved in alkylglycerophosphoethanolamine phosphodiesterase activity?
The primary gene is ENPP2, which encodes autotaxin, the enzyme responsible for this activity. Other genes include LPA receptors (LPAR1-6) and lipid phosphate phosphatases (LPP1-3) that regulate the pathway.
What is the role of autotaxin in cancer?
Autotaxin (ENPP2) is overexpressed in many cancers and generates LPA, which promotes tumor cell proliferation, migration, and survival. It also contributes to the tumor microenvironment and metastasis.
How is lysophospholipase D activity measured?
It is typically measured using fluorogenic or radiolabeled substrates, such as lysophosphatidylcholine analogs, and detecting the release of choline or ethanolamine. Mass spectrometry can also quantify LPA products.
What diseases are associated with LPA signaling?
LPA signaling is implicated in cancer, pulmonary fibrosis, neuroinflammation, atherosclerosis, and reproductive disorders, among others.
Can CRISPR be used to study alkylglycerophosphoethanolamine phosphodiesterase activity?
Yes, CRISPR knockout of ENPP2 or LPA receptors, point mutations in catalytic residues, and overexpression models are powerful tools to dissect the function of this activity in health and disease.
What are the substrates of autotaxin?
Autotaxin primarily hydrolyzes lysophosphatidylcholine to produce LPA, but it also acts on other lysophospholipids, including alkylglycerophosphoethanolamine, reflecting its lysophospholipase D activity.
Are there inhibitors of autotaxin?
Yes, several small-molecule inhibitors of autotaxin have been developed, including benzoxaboroles, which are used in research and have therapeutic potential.
How does LPA signal inside cells?
LPA binds to G-protein-coupled receptors (LPAR1-6), activating downstream pathways such as MAPK/ERK, RhoA, and PI3K/AKT, which regulate proliferation, migration, and survival.
What model systems are used to study this activity?
Common models include cancer cell lines, primary fibroblasts, microglia, and genetically modified mice (knockout, knock-in, transgenic). CRISPR-edited cell lines are increasingly used for precise functional studies.
Conclusion
Alkylglycerophosphoethanolamine phosphodiesterase activity (GO:0047391) is a key enzymatic function in lysophospholipid metabolism, primarily mediated by autotaxin (ENPP2). Its product, LPA, is a potent signaling lipid involved in numerous physiological and pathological processes, including cancer, fibrosis, and neuroinflammation. Understanding the regulation and function of this activity is essential for developing targeted therapies. EDITGENE offers comprehensive CRISPR-based services to facilitate research on this pathway, from gene knockout to overexpression and library screening.
References
- 1. Law SH et al.. 2019. An Updated Review of Lysophosphatidylcholine Metabolism in Human Diseases.. Int J Mol Sci 20(5) PMID: 30845751
- 2. Volkmann ER et al.. 2024. Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis.. Eur Respir Rev 33(172) PMID: 39009409
- 3. Plastira I et al.. 2020. MAPK signaling determines lysophosphatidic acid (LPA)-induced inflammation in microglia.. J Neuroinflammation 17(1):127 PMID: 32326963
- 4. Auciello FR et al.. 2019. A Stromal Lysolipid-Autotaxin Signaling Axis Promotes Pancreatic Tumor Progression.. Cancer Discov 9(5):617-627 PMID: 30837243
- 5. Kraljić K et al.. 2019. Benzoxaboroles-Novel Autotaxin Inhibitors.. Molecules 24(19) PMID: 31547058
- 6. Perrakis A et al.. 2014. Autotaxin: structure-function and signaling.. J Lipid Res 55(6):1010-8 PMID: 24548887
- 7. Lu L et al.. 2024. ENPP2 promotes progression and lipid accumulation via AMPK/SREBP1/FAS pathway in chronic lymphocytic leukemia.. Cell Mol Biol Lett 29(1):159 PMID: 39731014
- 8. Nadhan R et al.. 2025. Decoding lysophosphatidic acid signaling in physiology and disease: mapping the multimodal and multinodal signaling networks.. Signal Transduct Target Ther 10(1):337 PMID: 41068071
